San Antonio Breast Cancer Symposium
|Thursday, December 10 from 9:15 - 11:30 am
General Session 1 -- Exhibit Hall D
#13 @ 9:45 am
Goss P, Ingle J, Martino S, Robert N, Muss H, Shepherd L, Pritchard KI, Livingston R, Davidson N, Perez E, Cameron D, Whelan T, Palmer M, Tu D. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the Canadian Cancer Trials Group MA17 Trial. San Antonio Breast Cancer Symposium, 2009.
#14 @ 10:00 am
Stearns V, Chapman J-A, Ma C, Ellis MJ, Ingle J, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maître A, Elliott C, Shepherd L, Goss P. Treatment-emergent symptoms and the risk of breast cancer recurrence in the Canadian Cancer Trials Group MA.27 adjuvant aromatase inhibitor trial. San Antonio Breast Cancer Symposium, 2009.
#15 @ 10:15 am
Ingle J, Schaid D, Goss P, Mushiroda T, Chapman J-A, Kubo M, Jenkins G, Batzler A, Liu M, Shepherd L, Ellis M, Flockhart D. A genome-wide association study in patients experiencing musculoskeletal adverse events on aromatase inhibitors as adjuvant therapy in early breast cancer entered on Canadian Cancer Trials Group Trial MA.27. A Pharmacogenetics Research Network-RIKEN Collaboration. San Antonio Breast Cancer Symposium, 2009.
Friday, December 11 from 5:30 - 7:30 pm
Poster Session #3 -- Detection/Diagnosis: Circulating Markers
Exhibit Halls A-B
Ali S, Chapman J-AW, Lipton A, Leitzel K, Pritchard KI, Pu X, Wilson C, Carney WP, Shepherd L, Pollak M. Examination Of TIMP-1 levels and relapse-free survival for patients In Canadian Cancer Trials Group MA.14 who received adjuvant tamoxifen +/- octreotide LAR. San Antonio Breast Cancer Symposium, 2009.
Saturday, December 12 from 7:00 - 9:00 pm
Poster Session #4 -- Prognosis and Response Predictions: Prognostic Factors & Biomarkers-Clinical Testing and Validation I
Exhibit Halls A-B
Prognostic and Predictive Impact of Intrinsic Biological Classification by Chia SK, Ung K, Bramwell V, Tu D, Perou CM, Ellis MJ, Bernard PS, Vickery T, Mardis E, Cheang M, Pritchard K, Shepherd L, Nielsen TO. Immunohistochemistry (IHC) and QPCR for Adjuvant Tamoxifen in Pre-Menopausal Breast Cancer: Results from the Canadian Cancer Trials Group MA.12 Trial.